A case of sensory ataxic Guillain-Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer).

Fukushima, T; Tomita, M; Ikeda, S; Hattori, N

Fukushima, T; Tomita, M; Ikeda, S; Hattori, N.

Affiliation

Fukushima T; From the Department of Neurology, Toyota Kosei Hospital, 500-1 Ibobara Josui-cho, Toyota City JP470-0396, Japan.
Tomita M; From the Department of Neurology, Toyota Kosei Hospital, 500-1 Ibobara Josui-cho, Toyota City JP470-0396, Japan.
Ikeda S; From the Department of Neurology, Toyota Kosei Hospital, 500-1 Ibobara Josui-cho, Toyota City JP470-0396, Japan.
Hattori N; From the Department of Neurology, Toyota Kosei Hospital, 500-1 Ibobara Josui-cho, Toyota City JP470-0396, Japan.

QJM ; 115(1): 25-27, 2022 01 21.

Article in En | MEDLINE | ID: mdl-34871447

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Guillain-Barre Syndrome / COVID-19 Limits: Humans Language: En Journal: QJM Journal subject: MEDICINA Year: 2022 Document type: Article Affiliation country: Japón

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google